5 Key Takeaways

• 1

  In the phase 3 TroFuse-005 trial, 776 patients with advanced or recurrent endometrial cancer received sacituzumab tirumotecan or physician’s choice of doxorubicin or paclitaxel.

• 2

  At a median follow-up of 14 months, median overall survival was 19 months with sacituzumab tirumotecan and 12.1 months with chemotherapy, a 32% lower risk of death.

• 3

  Median progression-free survival was 7.2 months with sacituzumab tirumotecan and 3.9 months with chemotherapy, a 41% lower risk of progression or death.

• 4

  Objective response rates were 35.1% with sacituzumab tirumotecan and 17.3% with chemotherapy; median response duration was 11.1 and 6.9 months, respectively.

• 5

  Grade 3 or higher treatment-related adverse events occurred in 54.4% of sacituzumab tirumotecan recipients and 41.4% of chemotherapy recipients; the drug remains investigational.